Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Shantelle LaFayette
United States Patent And Trademark Office Issues Revised Guidance On Inventorship For AI-Assisted Inventions
Mayer Brown are most popular: within Wealth Management topic(s) On November 28, 2025, the United States Patent and Trademark Office (USPTO) issued revised examination guidance on inventorship for AI‑assisted inventions. The guidance rescinds the USPTO's prior approach, clarifies the governing legal standards, and provides updated instructions for practitioners and applicants in light of recent developments in artificial intelligence.
United States Patent and Trademark Office Issues Revised Guidance on Inventorship for AI-Assisted Inventions | JD Supra
On November 28, 2025, the United States Patent and Trademark Office (USPTO) issued revised examination guidance on inventorship for AI‑assisted inventions. The guidance rescinds the USPTO’s prior approach, clarifies the governing legal standards, and provides updated instructions for practitioners and applicants in light of recent developments in artificial intelligence.
Intellectual Property
Many of us feel the daily pull toward coffee, and perhaps likewise toward PTAB decisions about coffee makers. I found interesting a recent pair of IPR decisions successfully brought by the Swiss Nespresso against German competitor K-Fee. This post delves into these cases and what I call the 'glove doesn't fit' fallacy in patent law obviousness doctrine; it also provides a discussion of how written description continues to be a risk, even in inter partes review (IPR) proceedings.
Nestle, Nespresso Axe Two K-Fee Coffee Pod Patents At Tribunal
Nestle, Nespresso Axe Two K-Fee Coffee Pod Patents At Tribunal MB Mayer Brown More Mayer Brown is a distinctively global law firm, uniquely positioned to advise the world’s leading companies and financial institutions on their most complex deals and disputes. We have deep experience in high-stakes litigation and complex transactions across industry sectors, including our signature strength, the global financial services industry. Nespresso USA Inc.
Talk In The Biotech Industry Has Focused On The Broad Institute's Big Win—But Will Continued Scientific Development Minimize Its Impact? - Intellectual Property - United States
To print this article, all you need is to be registered or login on Mondaq.com. The CRISPR-Cas9 gene editing system has revolutionized genetic engineering. Over the last decade, this technology has exploded at a breathtaking pace due to its simplicity, scalability, affordability and adaptability.
Talk in the Biotech Industry has Focused on the Broad Institute’s Big Win-But Will Continued Scientific Development Minimize Its Impact?
The CRISPR-Cas9 gene editing system has revolutionized genetic engineering. Over the last decade, this technology has exploded at a breathtaking pace due to its simplicity, scalability, affordability and adaptability. Currently, the CRISPR-Cas9 system is employed in molecular biology laboratories all around the world and has been used to edit the genomes of a myriad of organisms from bacteria to yeasts to plants to mammals.
Federal Court finds inducement of infringement at summary trial under the PM(NOC) Regulations
The Federal Court has confirmed that issues of infringement, including by inducement, may be decided by summary trial in an infringement action under the Patented Medicines (Notice of Compliance) Regulations (the Regulations). The Court rejected the Defendant’s attempt to avoid infringement based on the scope of its abbreviated new drug submission and product monograph (PM).
PM(NOC) Regulations Do Not Preclude Defendants From Amending The Statement Of Defence
To print this article, all you need is to be registered or login on Mondaq.com. A defendant in a patent infringement action under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations was allowed to amend its defence to include invalidity allegations not found in the Notice of Allegation.
PM(NOC) Regulations do not preclude defendants from amending the statement of defence
A defendant in a patent infringement action under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations was allowed to amend its defence to include invalidity allegations not found in the Notice of Allegation. Background In an action under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (Regulations) concerning three patents, the defendant sought to amend its statement of defence to add new prior art references and invalidity allegations.
IP Monitor: Quebec Superior Court Dismisses Application For Disavowal Of Admissions Of Patent Invalidity
To print this article, all you need is to be registered or login on Mondaq.com. The plaintiffs in a patent infringement proceeding before the Quebec Superior Court sought to disavow several statements made during trial by their patent counsel involving one of the two patents in suit. The patent counsel acknowledged exceeding the scope of his mandate by making the impugned statements. Failing to raise this issue at the first opportunity, the court found, was sufficient to dismiss the motion.
La Cour supérieure du Québec rejette une demande en désaveu de déclarations d'invalidité de brevet
Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice): Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below. Mondaq has a "free to view" business model.
La Cour supérieure du Québec rejette une demande en désaveu de déclarations d’invalidité de brevet
Dans le cadre de poursuites en contrefaçon de brevet devant la Cour supérieure du Québec, les demandeurs contestaient plusieurs déclarations faites pendant le procès par l’un de leurs avocats (l’avocat-conseil) portant sur l’un des deux brevets en litige. L’avocat-conseil a reconnu avoir outrepassé la portée de son mandat en formulant les déclarations contestées. Le tribunal a conclu au rejet de la demande en raison du fait que le désaveu n’a pas été soulevé à la première occasion.
Dosing regimen patent found valid and infringed in the second decision under the new PM(NOC) Regulations
In the second trial judgment under the new Patented Medicine (Notice of Compliance) Regulations, the Federal Court (FC) found for the Plaintiffs, Janssen Inc. and Janssen Pharmaceutica N.V., and enjoined Teva Canada Limited (Teva) from making, constructing, using or selling paliperidone palmitate (paliperidone) in accordance with its abbreviated new drug submission.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Shantelle
Contact Shantelle, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack